< back to search

Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.

Kivitz, Alan J   •   Wagner, Ulf   •   Dokoupilova, Eva   •   Supronik, Jerzy   •   Martin, Ruvie   •   Talloczy, Zsolt   •   Richards, Hanno B   •   Porter, Brian

published in: Rheumatology and therapy



endpoint

Secukinumab has (optional: compared with placebo) proved to be better.
general condition better


basics

diagnosis:
ankylosing spondylitis

localization:
not specified

method:
conservative therapy → injection therapy
conservative therapy → injection therapy
conservative therapy → injection

publication details

10.1007/s40744-018-0123-5
pubmed
30121827
2018
Journal Article
randomized controlled trial
yes
prospective
1+

▼
▲